Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 5/20 | 0.33 |
| ▸ | JAK3 | P52333 | 5/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18421581 | 1.00 | MEN1 (0.41) | MEN1KMT2AMAPTMAPKAPK2CHEK1 | |
| SCHEMBL17545885 | 1.00 | MEN1 (0.41) | MEN1KMT2AMAPTMAPKAPK2CHEK1 | |
| SCHEMBL18419033 | 0.94 | MEN1 (0.38) | MEN1KMT2AMAPTMAPKAPK2JAK1 | |
| SCHEMBL17545937 | 0.79 | PIK3CD (0.42) | CHEK1KCNH2JAK1JAK2 | |
| SCHEMBL18425094 | 0.78 | BTK (0.38) | MEN1KMT2AJAK3 | |
| SCHEMBL17545875 | 0.78 | JAK2 (0.40) | MEN1KMT2AMAPTJAK1JAK3 | |
| SCHEMBL18465519 | 0.78 | SMN1; SMN2 (0.47) | MEN1KMT2AMAPTMAPKAPK2CHEK1 | |
| SCHEMBL27028314 | 0.77 | CHEK2 (0.33) | MEN1KMT2AMAPTMAPKAPK2JAK1 | |
| SCHEMBL2732213 | 0.77 | GPR119 (0.41) | MEN1KMT2AJAK1JAK3JAK2 | |
| SCHEMBL17546141 | 0.74 | GPR119 (0.44) | JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | TEC, ABL1, LCK | MEN1 2539/4885KMT2A 1089/4885MAPT 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.